Peroxiredoxins in disease biology: molecular mechanisms and therapeutic opportunities
- 1The First Affiliated Hospital of Soochow University , , ,
Abstract
Peroxiredoxins (PRDXs) are thiol-specific antioxidant enzymes that maintain cellular redox balance and regulate signaling pathways. They participate in the development of cancer, neurodegenerative disorders, cardiovascular diseases, inflammatory conditions, and infectious diseases. In cancer, PRDXs are frequently overexpressed and promote tumor progression, metastasis, and treatment resistance through interactions with oncogenic pathways. In neurodegenerative and cardiovascular diseases, by contrast, they support cell survival by limiting oxidative damage. Therapeutic strategies directed at PRDXs include small-molecule inhibitors, activators, and gene therapy. PRDX inhibitors sensitize tumor cells to oxidative damage, whereas PRDX activators confer neuroprotection; the principal obstacles are achieving isoform specificity and limiting off-target effects. Here we review the structure and biology of the PRDX family, its isoform- and context-dependent functions across these disease settings, and the evidence supporting PRDXs as therapeutic targets and prognostic biomarkers.
Related
- Unraveling the pyroptosis-mitophagy axis: from molecular mechanisms to therapeutic opportunities
- Crosstalk between PI3K/AKT signaling and epigenetic regulation in hepatocellular carcinoma: molecular mechanisms and therapeutic opportunities
- Microbiome-mitochondria crosstalk in neuro-oncology: molecular mechanisms, immunometabolic reprogramming, and therapeutic opportunities
- Extracellular Vesicles in Molecular Crosstalk and Disease Pathogenesis: A Comprehensive Review on Mechanisms and Therapeutic Prospects
- Gut Microbiota-Host Redox Crosstalk: Molecular Mechanisms, Disease Pathogenesis, and Therapeutic Interventions.
BibTeX
@article{jiang2026peroxiredoxins,
title = {{Peroxiredoxins in disease biology: molecular mechanisms and therapeutic opportunities}},
author = {Yunjia Jiang and Xin Yao and Xuqi Sun and Xiaotong Wang and Ping Xia and Minggang Wei},
journal = {Frontiers in molecular biosciences},
year = {2026},
month = oct,
doi = {10.3389/fmolb.2026.1955614},
url = {https://europepmc.org/article/PMC/PMC13716948},
note = {CC BY},
}
RIS
TY - JOUR
TI - Peroxiredoxins in disease biology: molecular mechanisms and therapeutic opportunities
AU - Yunjia Jiang
AU - Xin Yao
AU - Xuqi Sun
AU - Xiaotong Wang
AU - Ping Xia
AU - Minggang Wei
PY - 2026
DA - 2026/10/15
JO - Frontiers in molecular biosciences
DO - 10.3389/fmolb.2026.1955614
UR - https://europepmc.org/article/PMC/PMC13716948
AB - Peroxiredoxins (PRDXs) are thiol-specific antioxidant enzymes that maintain cellular redox balance and regulate signaling pathways. They participate in the development of cancer, neurodegenerative disorders, cardiovascular diseases, inflammatory conditions, and infectious diseases. In cancer, PRDXs are frequently overexpressed and promote tumor progression, metastasis, and treatment resistance through interactions with oncogenic pathways. In neurodegenerative and cardiovascular diseases, by contrast, they support cell survival by limiting oxidative damage. Therapeutic strategies directed at PRDXs include small-molecule inhibitors, activators, and gene therapy. PRDX inhibitors sensitize tumor cells to oxidative damage, whereas PRDX activators confer neuroprotection; the principal obstacles are achieving isoform specificity and limiting off-target effects. Here we review the structure and biology of the PRDX family, its isoform- and context-dependent functions across these disease settings, and the evidence supporting PRDXs as therapeutic targets and prognostic biomarkers.
SN - 2296-889X
ER -